Clinical observation of TAS-102 combined with sindillizumab and regorafenib in treatment of advanced colorectal cancer patients who failed to receive standard treatment
Li Yang
Zhang Jing
Shi Xin
Wang Caixia
Abstract：Objective To investigate the clinical efficacy of TAS-102 combined with sindillizumab and regorafenib in the treatment of advanced colorectal cancer(CRC)patients who failed to receive standard treatment.Methods From Jan-uary 2022 to January 2024,92 patients with advanced CRC who failed to receive standard treatment were treated in the On-cology Department of the Second People's Hospital of Taizhou,Jiangsu Province.They were divided into observation group and control group by random number table method,with 46 cases in each group.The control group was treated with sindili-zumab combined with regorafenib,and the observation group was additionally treated with TAS-102.The clinical efficacy,serum tumor markers[carbohydrate antigen 242(CA242),CA72-4,CA19-9,carcinoembryonic antigen(CEA)]levels,immune function indicators[(CD3+,CD4+,CD4+/CD8+),natural killer cells(NK)],serum angiogenesis indicators[vascular endo-thelial growth factor(VE)]were compared between 2 groups GF),angiopoietin-2(Ang-2)]levels and incidence of adverse re-actions.Results The disease control rate of observation group was higher than that of control group(x2/P=4.696/0.030).Compared with before treatment,the levels of serum CA242,CA72-4,CA19-9 and CEA in 2 groups were decreased after treatment(t/P=16.647/＜0.001,12.658/＜0.001,15.584/＜0.001,31.807/＜0.001,25.051/＜0.001;20.170/＜0.001,23 201/＜0.001,38.735/＜0.001),CD3+,CD4+,CD4+/CD8+,NK levels increased(t/P=4.618/＜0.001;4.909/＜0.001;4.782/＜0.001;4.447/＜0.001;7.921/＜0.001;9.915/＜0.001;8.925/＜0.001;6.591/＜0.001),serum VEGF and Ang-2 levels decreased(t/P=7.043/＜0.001;14.808/＜0.001;13.106/＜0.001;19.474/＜0.001),and the decrease/increase in the observation group was greater than that in the control group(t/P=9.298/＜0.001;7.549/＜0.001;10.512/＜0.001;16.647/＜0.001;3.432/＜0.001;4.938/＜0.001;4.958/＜0.001;2.747/＜0.001;6.014/＜0.001;4.749/＜0.001);There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion TAS-102 combined with sindillizumab and regorafenib can im-prove immune function,reduce tumor markers and angiogenesis indexes in advanced CRC patients who have failed to re-ceive standard treatment,with significant effects and high safety.
Keywords：Advanced colorectal cancerTAS-102SindilimabRegofenilTherapeutic effect
Publication Date：2025-02-17
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)